

# Questions on which the views of the Committee are sought

## In this guide

### [In this guide](#)

1. [Introduction, Background and Literature Search - PFAS/2023/06](#)
2. [In vivo liver toxicity studies - PFAS/2023/06](#)
3. [Endpoints Investigated and Summary of Results - PFAS/2023/06](#)
4. [Liver Weight - PFAS/2023/06](#)
5. [Clinical chemistry- PFAS/2023/06](#)
6. [Liver histopathology - PFAS/2023/06](#)
7. [Effects on gene expression - PFAS/2023/06](#)
8. [Serum/plasma PFAS levels - PFAS/2023/06](#)
9. [Discussion - PFAS/2023/06](#)
10. [Table 1 Lowest POD for PFAS based on liver effects - PFCAs](#)
11. [Table 2 Lowest POD for PFAS based on liver effects - PFSAAs](#)
12. [Questions on which the views of the Committee are sought - PFAS/2023/06](#)
13. [List of Abbreviations - PFAS/2023/06](#)
14. [References - PFAS/2023/06](#)

**This is a paper for discussion. This does not represent the views of the Committee and should not be cited.**

192. Members are invited to consider the following questions:

- i). Are there any specific papers that the subgroup would like to review in more detail?
- ii). Recovery is assessed in a minority of studies. Should the N/LOAEL be based on effects seen at the end of treatment or after the recovery period?

iii). Liver effects seen in developmental studies are presented for dams and offspring. The N/LOAELs are based on effects in the dam only. Does the subgroup agree with excluding effects seen in offspring, which will be reported in subsequent papers?

**IEH Consulting under contract supporting the UKHSA COT Secretariat**

**December 2023**